Search PubMed⌕ Search

Biomedical subjects

P Geelen

Publications and source records attributed to P Geelen.

34 records · Page 2Linked to original sources
PubMed1998

Neck pounding during sinus rhythm: a new clinical manifestation of dual atrioventricular nodal pathways.

OBJECTIVE: To determine the clinical and electrophysiological characteristics of patients with paroxysmal palpitations and neck pounding during sinus rhythm. METHODS: Clinical, electrocardiographic, and electrophysiological characteristics of six patients with paroxysmal palpitations and neck pounding during sinus rhythm were studied in basal conditions and when symptomatic. Response to treatment was observed. RESULTS: Baseline ECGs were normal (four patients) or had first degree atrioventricular block with intermittent PR shortening. During symptoms, narrow QRS rhythms were seen without visible P waves (three patients) or with P waves partially hidden in the QRS complex (three patients). Dual atrioventricular nodal pathways were found in all five patients who had electrophysiological studies. In these patients the slow pathway conduction time was long enough (mean (SD), 425 (121) ms) for ventricular activation after slow pathway conduction during sinus rhythm to coincide with the next atrial depolarisation, causing neck pounding during exercise (four patients) or at rest (two patients). Tachycardia was not induced in any patient. Medical treatment aggravated symptoms in three patients. A pacemaker was successfully used in two. CONCLUSIONS: Neck pounding during sinus rhythm is a clinical manifestation of dual atrioventricular nodal pathways. Medical treatment may aggravate symptoms but a pacemaker may offer definitive relief.

Adult↗
PubMed1997

A prospective hemodynamic evaluation of patients with chronic atrial fibrillation undergoing radiofrequency catheter ablation of the atrioventricular junction.

A prospective invasive hemodynamic evaluation in 11 unselected patients with medically refractory chronic atrial fibrillation undergoing radiofrequency catheter ablation of the atrioventricular junction was performed. The resultant rate regulation and control caused a hemodynamic and symptomatic improvement despite persistent fibrillation at the atrial level.

Aged↗
PubMed1997

Experience with implantable cardioverter defibrillator therapy in elderly patients.

AIM: Concern exists about the benefit of implantable defibrillator therapy in elderly patients. We assessed the utility of implantable defibrillator therapy and its effect on mortality in patients 70 years and older and compared results in this group to those in younger patients. METHODS AND RESULTS: Thirty-two out of 200 consecutive patients (16%) were 70 years or older at the time of implantation of a defibrillator. When comparing elderly to younger patients no significant differences were noted with respect to presenting arrhythmia, left ventricular ejection fraction or presence of an old myocardial infarction. Elderly patients had a higher prevalence of ischaemic heart disease, while in the younger group more patients had idiopathic ventricular tachycardia. Cumulative survival curves (Kaplan-Meier method) for all-cause mortality, sudden cardiac death and non-sudden cardiac death were constructed for elderly and younger patients. No significant differences for cumulative survival from all-cause mortality (75 vs 74%), sudden cardiac death (0 vs 4%) and non-sudden cardiac death (97 vs 93%) were found. The incidence of appropriate shocks during follow-up was comparable (65 vs 72%). CONCLUSION: Implantable defibrillator therapy was effective in preventing sudden cardiac death in the elderly. Total mortality was similar to younger patients at a follow-up of 19 +/- 14 and 25 +/- 19 months, respectively. Age itself should be no contraindication to implantable cardioverter defibrillator therapy.

Aged↗
PubMed1997

The value of DDD pacing in patients with an implantable cardioverter defibrillator.

Although the beneficial effects of DDD pacing are well known, currently available ICDs provide only fixed rate ventricular antibradycardia pacing. In a consecutive series of 139 patients with ICDs, we have analyzed the need for antibradycardia pacing and the indications for DDD pacing. We also report our initial experience with the Defender 9001 (ELA Medical, France) DDD-ICD. Out of 139 patients, 25 (18%) were in need of antibradycardia pacing. Ten patients already had a pacemaker at the time of ICD implantation and ten other patients had a conventional pacemaker indication at that time. Five patients became pacemaker dependent during a follow-up of 20 +/- 8 months. The disorders necessitating pacemaker therapy were high degree AV conduction disturbances in 72%, sick sinus syndrome in 12%, and AF with a slow ventricular response in 16% of patients. Based upon current indications, DDD pacing was indicated in 20 (80%) of 25 patients. The Defender 9001 DDD-ICD (ELA Medical) was used in two patients with ischemic cardiomyopathy and pacemaker syndrome with VVI pacing. Cardiac output during DDD pacing increased by 36% in one patient with an increase in VO2 max during exercise of 29%. The other patient showed an increase in cardiac output of 50% with DDD pacing, and, while unable to exercise with VVI pacing, had a VO2max of 24 mL/kg per minute during DDD pacing. Up to 18% of our ICD patients are in need of antibradycardia pacing. Of these pacemaker dependent patients, 80% have an indication for DDD pacing. Our first clinical experience with a DDD-ICD confirms the hemodynamic benefit of AV synchronous pacing in ICD patients with pacemaker syndrome.

Aged↗
PubMed1997

Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction.

Two hundred thirty-five patients underwent RF catheter ablation of AV conduction for symptomatic drug refractory AF (84%), atrial flutter (9%), and atrial tachycardia (7%). In the first 100 patients, postablation pacing was not prospectively set at any specific rate and was always < or = 70 beats/min. In the next 135 patients, postablation pacing was prospectively set at 90 beats/min for 1-3 months. Six of the first 100 patients (6%) had VF or sudden death after the RF procedure and none (0%) of the next 135 patients did (P < 0.05). One of the six patients had recurrent VF 4 days after the ablation. Five patients were successfully resuscitated and one patient died. There were no statistically significant differences between patients with and without (aborted) sudden death or between the first 100 and the next 135 patients with respect to age, sex, underlying heart disease, EF, number of RF applications, or left-or right-sided approach of the procedure. VF mostly occurred during episodes of slow ventricular escape rhythms or during slow ventricular pacing. We conclude that malignant ventricular arrhythmias and sudden death are possible complications of RF ablation of the AV function. The mechanism of these complications could have a bradycardia dependent nature and it seems that the occurrence of malignant arrhythmias can be prevented by temporarily pacing the heart at relatively fast rates immediately after ablation.

Aged↗
PubMed1997

Some electrocardiographic patterns predicting sudden cardiac death that every doctor should recognize.

In recent years major advances have been made in the recognition and treatment of candidates to sudden cardiac death. These advances include very sophisticated diagnostic and therapeutic techniques, such as genetic testing and the implantable cardioverter-defibrillator, new knowledge coming from large multicenter trials, particularly about the poor efficacy of so-called "antiarrhythmic" drugs, but also very important advances have been made in improving the diagnostic value of simple techniques such as the twelve-lead electrocardiogram. In this article six different electrocardiographic patterns associated to sudden cardiac death are described. Some patterns, like left ventricular hypertrophy or low voltage in the limb electrocardiographic leads, are frequent and the incidence of sudden death in these patients is relatively low, although clearly higher as compared to individuals with a normal electrocardiogram. On the other hand, other patterns which are rarer (like the long QT syndrome or the syndrome of right bundle branch block and ST segment elevation in V1-V3) are associated to a very high rate of sudden death. Because sudden death can be prevented in many cases, every doctor should be able to recognize these types of electrocardiograms.

Arrhythmogenic Right Ventricular Dysplasia↗
PubMed1995

New developments and treatment strategies in patients with supraventricular tachyarrhythmias.

The mechanisms, clinical presentation and therapy of supraventricular tachycardias are discussed. The therapy has changed from palliation by means of anti-arrhythmic drugs into definitive cure by ablation of the arrhythmia substrate. Radiofrequency energy causes tissue damage by heating and appears to be a safe method for catheter ablation of supraventricular tachycardias. We report a 97% success rate for radiofrequency ablation of 195 accessory atrioventricular pathways thereby curing these patients from circus-movement tachycardia and paroxysmal atrial fibrillation. Complications occurred in 3% of patients. One hundred seventy-two patients with atrioventricular nodal reentrant tachycardia, caused by reentry within dual AV-nodal pathways, were treated by selectively ablating one of the pathways with non-inducibility of the arrhythmia afterwards in 97% of the cases. Nine percent of patients had a recurrence but were successfully treated in a second session. The procedure was complicated by complete AV-block in 4% of patients. The disappointing medical treatment of atrial fibrillation and the fact that atrial fibrillation can be the cause of a reversible form of heart failure (tachycardiomyopathy), induced the clinical application of alternative forms of treatment. Ablation of the normal atrioventricular conduction system by using radiofrequency energy was performed with a 100% success rate in 121 patients. After implantation of a ventricular pacemaker it is possible to control and regulate the ventricular rhythm leading to rate control and amelioration of ventricular performance.

Atrial Fibrillation↗
PubMed1995

Radiofrequency ablation of atrioventricular node reentrant tachycardia: experience in 302 patients.

Radiofrequency catheter ablation was performed in 302 consecutive patients with drug refractory atrioventricular (AV) node reentrant tachycardia. Fast pathway ablation was attempted in 167 patients and was successful in 161 patients (96.4%). At a mean follow-up of 24 +/- 12 months, there were 21 tachycardia recurrences (12.5%). A second fast pathway ablation was attempted in 17 patients and was successful in all but 1 patient. Permanent complete AV block occurred in 12 patients (7.2%). Among the latter, late AV block was noted in 5 patients. Final success without pacemaker implantation was accomplished in 151 patients (90.4%). Slow pathway was attempted in 135 patients and was successful in 130 patients (96.3%). Three patients in whom slow pathway ablation failed underwent successful fast pathway ablation during the same session. At a mean follow-up of 14 +/- 11 months, there were 16 tachycardia recurrences (11.8%). A second slow pathway ablation was attempted in 16 patients and was successful in all but 1 patient. Permanent complete AV block occurred in 3 patients (2.2%). An additional patient developed 2 : 1 AV block during exercise, 3 months after ablation. Final success without pacemaker implantation was achieved in 129 patients (95.5%). Fast and slow pathway ablation had similar success and recurrence rates, procedure and fluoroscopy times, and number of radiofrequency pulses. However, the incidence of permanent complete AV block was higher following fast pathway ablation (p = 0.049). Although equally effective, slow pathway ablation is safer than fast pathway ablation, therefore, should be the first choice approach for treatment of AV node reentrant tachycardia.

Adolescent↗
PubMed1992

Incidence and timing of recurrences of sudden death and ventricular tachycardia during antiarrhythmic drug treatment after myocardial infarction.

Incidence and timing of recurrences of sustained ventricular tachycardia (VT) or sudden death were studied in 206 patients who survived their first episode of ventricular fibrillation (VF; n = 52) or sustained VT (n = 154) after myocardial infarction. All patients were treated with (empirically selected) antiarrhythmic drugs; 49% received amiodarone. After a mean follow-up of 36 months, 64 patients (41%) in the VT group and 10 (19%) in the VF group had nonfatal VT recurrences. Sudden death occurred in 22 (14%) and 9 (17%) patients in the VT and VF groups, respectively. Incidence of sudden death had 2 peaks at approximately 3 and 12 months. Nonfatal VT recurrences were more frequent (most often occurring in first 6 months) in the VT than in the VF group. Sudden death occurred during the following 3 years in only 10% of patients who survived 1 year. There was a much higher incidence of sudden death in patients with left ventricular ejection fraction (LVEF) less than or equal to 40% than in those with LVEF greater than 40% (28 of 65 vs 3 of 141; p less than 0.0001), but no relation between LVEF and nonfatal VT recurrences.

Aged↗
PubMed1992

Identification of patients at high risk for recurrence of sustained ventricular tachycardia after healing of acute myocardial infarction.

A prognostic index for nonfatal recurrences of ventricular tachycardia (VT) was developed using a retrospective analysis of a group of 206 patients with sustained monomorphic VT or ventricular fibrillation (VF) after healing of acute myocardial infarction. 74 patients (36%) (64 with VT and 10 with VF) had recurrences of sustained monomorphic VT during 3.4 +/- 9 years of follow-up. Three clinical variables were selected and weighted by stepwise logistic discriminant analysis of the study group. They were coded as follows: interval of myocardial infarction to arrhythmia (less than 2 months = 1; 2 to 6 months = 2; greater than 6 months = 3), drug therapy with or without sotalol (with = 1, without = 2), and VT or VF as the presenting arrhythmia (VT = 1, VF = 2). The prognostic index was: 3.41 - (0.56 x interval) - (1.94 x therapy) + (0.86 x arrhythmia). This index was validated prospectively in a test group of 158 consecutive patients with VT or VF after healing of acute myocardial infarction. Patients were allocated into different classes with decreasing prognostic index values associated with increasing risk for recurrences of VT. In the test group, 27 of 158 (17%) patients (22 with VT and 5 with VF) had recurrences of VT (follow-up of 2 +/- 2 years). Two risk classes of patients were identified: high risk for recurrences of VT (61%) corresponding to patients with a negative index; and low risk (4%) consisting of those with a positive index. Thus, using O as the cutoff point, the sensitivity, specificity, and positive and negative predictive values were 81, 89, 62 and 96%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1986

Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.

Eighty-eight previously untreated patients with stage III and IV epithelial ovarian carcinoma were treated with primary or delayed (secondary) optimal debulking surgery unless impossible, and combination chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide intravenously (IV) on day 1, every 4 weeks (CAP-I). In patients with no evidence of disease after six cycles of chemotherapy, a second-look laparotomy was performed. A pathologically confirmed complete response (CR) was obtained in 39% of the patients. The median progression-free survival period of all patients was 18 months and the median survival time 24 months. CAP-I is an effective chemotherapy schedule that can be administered with moderate toxicity and appears to enhance the cure rate in advanced ovarian carcinoma. The role of secondary surgery must be further defined.

Adult↗